Prof. Dr. med. Peter Fasching

Department of Obstetrics and Gynaecology Professur für Translationale Frauenheilkunde und Geburtshilfe

Interception of molecular relapse in breast cancer: The SURVIVE HERoes study (NCT06643585). (2026) Janni W, Friedl TW, Huesmann ST, Rack B, Heublein S, Schäffler H, Mehmeti F, et al. Journal article Prenatal Alcohol Exposure Predicts Academic Outcomes from Childhood to Adolescence: A Prospective Longitudinal Study Based on Meconium Ethyl Glucuronide (2026) Mestermann S, Broich M, Fasching P, Beckmann M, Kratz O, Hemetsberger J, Bailer M, et al. Journal article Interactions between genetic and epidemiological factors influencing mammographic density (2026) Suger AH, Chen H, Haas CB, Fan S, Scott CG, Bolla MK, Dennis J, et al. Journal article Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial (2026) Hörner M, Tretschock LM, John N, Ziegler P, Häberle L, Uhrig S, Goossens C, et al. Journal article Effect of postoperative hormonal therapy on pain following endometriosis surgery: a retrospective cohort study (2026) Blum S, Hofbeck L, Sipulina N, Au K, Lotz L, Giacomozzi M, Fasching P, et al. Journal article ASO Visual Abstract: Surgical Outcomes After Neoadjuvant Pembrolizumab Plus Chemotherapy for Triple-Negative Breast Cancer-Results from the Randomized, Placebo-Controlled Phase 3 KEYNOTE-522 Study (2026) Kuemmel S, Fasching P, Schmid P, Harbeck N, Takahashi M, Untch M, Boileau JF, et al. Journal article Physiologically-Based Pharmacokinetics of Ribociclib Drug–Drug Interactions and Organ Impairment Pharmacokinetics in Early Breast Cancer (2026) Ji Y, Huth F, Wang C, Schiller H, Combes FP, Crown J, Fasching P, et al. Journal article Clinical management of common toxicities with inhibitors targeting the PI3K/AKT/mTOR pathway in breast cancer (2026) Jhaveri KL, Iyengar NM, Turner NC, Rugo HS, O'Shaughnessy J, Barrios CH, Curigliano G, et al. Journal article, Review article Standardized patient coaching improves therapy persistence in patients with hormone receptor–positive, HER2–negative advanced/metastatic breast cancer treated with abemaciclib (2026) Welslau M, Fasching P, Semmler-Lins N, Mueller L, Belleville E, Rieger L, Uhrig S, et al. Journal article Large-scale meta-analysis and precision functional assays identify FANCM regions in which PTVs confer different risks for ER-negative and triple-negative breast cancer (2026) Billaud A, Figlioli G, Mooser C, Casamassima I, Azzoni V, Srivatsa J, Colombo M, et al. Journal article